Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma
Open Access
- 1 October 1998
- Vol. 83 (7) , 1355-1361
- https://doi.org/10.1002/(sici)1097-0142(19981001)83:7<1355::aid-cncr12>3.0.co;2-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Systemic therapy of malignant melanomaMedical Oncology, 1997
- Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival modelAnnals of Surgical Oncology, 1996
- Vaccine therapy for malignant melanomaCA: A Cancer Journal for Clinicians, 1996
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Serum manganese superoxide dismutase is a new tumour marker for malignant melanomaMelanoma Research, 1995
- Evaluation of melanin-related metabolites as markers of melanoma progressionCancer, 1994
- Monoclonal antibody‐based ELISA to detect glycoprotein tumor‐associated‐antigen‐specific immune complexes in cancer patientsJournal of Clinical Laboratory Analysis, 1992
- Characterization of a 90‐100 kDa tumor‐associated antigen in the sera of melanoma patientsInternational Journal of Cancer, 1990
- A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, AustraliaAnnals of Surgery, 1982
- Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasmsJournal of Surgical Research, 1980